Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
-
Int J Thyroidol. 2018 Nov;11(2):152-159. English. Original Article. https://doi.org/10.11106/ijt.2018.11.2.152
Song YS , Park YJ .
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. yjparkmd@snu.ac.kr
Abstract

Background and Objectives

Sodium-iodine symporter (NIS) is a marker for the degree of differentiation in thyroid cancer. The genetic factors or microenvironment surrounding tumors can affect transcription of NIS. In this study, we investigated the NIS mRNA expression according to mutational status and coexistent lymphocytic thyroiditis in papillary thyroid cancer (PTC).

Materials and Methods

The RNA expression levels of NIS in the samples from database of The Caner Genome Atlas (TCGA; n=494) and our institute (n=125) were analyzed.

Results

The PTCs with the BRAF(V600E) mutation and the coexistence of BRAF(V600E) and TERT promoter mutations showed significantly lower expression of NIS (p < 0.001, respectively), and those with BRAF-like molecular subtype also had reduced expression of NIS (p < 0.001). NIS expression showed a positive correlation with thyroid differentiation score (r=0.593, p < 0.001) and negative correlations with expressions of genes involved in ERK signaling (r=−0.164, p < 0.001) and GLUT-1 gene (r=−0.204, p < 0.001). The PTCs with lymphocytic thyroiditis showed significantly higher NIS expression (p=0.013), regardless of mutational status.

Conclusion

The NIS expression was reduced by the BRAF(V600E) mutation and MAPK/ERK pathway activation, but restored by the presence of lymphocytic thyroiditis.

Copyright © 2019. Korean Association of Medical Journal Editors.